BioSpace News Archive

Densitas® Inc., named Alexandra Bade Director, Global Sales and Operations to lead the company’s global market expansion.

Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3K α and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability.

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis.

Immunome, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19).

Mindset Pharma Inc. today announced that it will participate in the H.C. Wainwright 2 nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.

BrainStorm Cell Therapeutics Inc. today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), announced today that its chief executive officer, David Arthur, and other members of the Company’s management team will participate in the Benchmark Company Discovery One-on-One Investor Conference.

A plate sealer minimizes the sample evaporation during experimental workflow. It also eliminates human variability from plate sealing.

Masimo announced the findings of a study published in Clinical Medicine Insights: Pediatrics in which Dr. Harish Kumar and colleagues at IPE Global in New Delhi, India reported on their experience using the Masimo Rad-G® Pulse Oximeter to aid health providers in pneumonia case detection and management in more than 4,500 children under five years who presented with symptoms of acute respiratory infection.

Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, provides an update on its planned R&D Day on Tuesday, 30 November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.